Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy in female cancer patients (Japan, Phase 3)
jRCT2080224535Phase 3Completed
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of pembrolizumab in breast cancer (2 arms). Started Jan 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224535.